A novel cell-penetrating peptide (NCR) identified via machine learning delivered over 4x more cargo than the classic TAT peptide and, when fused to an antibody-binding domain, significantly enhanced the cytotoxicity of the antibody-drug conjugate T-DM1 against HER2-positive cancer cells.
>4x delivery vs TATThe NCR cell-penetrating peptide, discovered by machine learning, delivered over four times more cargo into cells than the widely used TAT peptide
What the researchers found
NCR peptide delivered >4x more EGFP into cells than TAT peptide and accumulated in lysosomes. Domain Z-NCR vector non-covalently bound T-DM1 and significantly enhanced its cytotoxicity against HER2-positive tumor cells (MTT assay) while maintaining drug specificity for HER2-expressing cells.
Why it matters
Antibody-drug conjugates like T-DM1 (trastuzumab emtansine) are important cancer therapies but their effectiveness is limited by inefficient cellular uptake and lysosomal delivery. This peptide-based enhancement strategy could improve ADC potency without changing the drug itself, potentially allowing lower doses or overcoming resistance.
The numbers in context
NCR was derived from the Rev protein of caprine arthritis-encephalitis virus. Screened from nuclear localization/export signal databases.
How the study worked
In vitro study: MLCPP2.0 machine learning algorithm screened nuclear localization/export signal databases for CPP candidates. Cell-penetrating activity verified by fluorescent tracing. NCR fused to domain Z (IgG Fc-binding) to create T-DM1 delivery vector. Cytotoxicity assessed by MTT assay in HER2-positive tumor cells.
Who was studied
Cancer cell lines and preclinical tumor models
What this study cannot tell us
In vitro only — no animal tumor models or pharmacokinetic data. The domain Z-NCR vector binds non-covalently, which may be unstable in blood. Only tested with T-DM1 against HER2-positive cells; generalizability to other ADCs unknown. No toxicity or immunogenicity assessment.
How to read the evidence
Rated preliminary: in vitro proof-of-concept only. Promising enhancement of ADC activity but no in vivo validation of efficacy, stability, or safety.
When this study was published
Published in 2024. Represents the cutting edge of AI-assisted peptide discovery for drug delivery.
The bigger picture
This work sits at the intersection of AI-driven peptide design and cancer drug delivery. As ADCs become a major class of cancer therapeutics, strategies to enhance their intracellular delivery could significantly improve clinical outcomes. The machine learning approach also demonstrates how computational tools can accelerate peptide discovery.
Questions still open
- Does the NCR-enhanced T-DM1 delivery translate to improved antitumor effects in animal models?
- Is the non-covalent binding between domain Z-NCR and T-DM1 stable enough for systemic delivery?
- Could this approach enhance ADCs that have failed due to insufficient lysosomal drug release?
Common questions
What are antibody-drug conjugates and why do they need better delivery?
How did machine learning help find this peptide?
Read the original research
A high hydrophobic moment arginine-rich peptide screened by a machine learning algorithm enhanced ADC antitumor activity.
Journal of peptide science : an official publication of the European Peptide Society, 30(12), e3628
Citation
Su, Ruo-Long; Cao, Xue-Wei; Zhao, Jian; Wang, Fu-Jun. (2024). A high hydrophobic moment arginine-rich peptide screened by a machine learning algorithm enhanced ADC antitumor activity.. Journal of peptide science : an official publication of the European Peptide Society, 30(12), e3628. https://doi.org/10.1002/psc.3628